New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse ...
Mayo Clinic’s Chelsee Jensen, PharmD, discusses FDA policy changes, biosimilar development hurdles, denosumab lessons, and ...
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to ...
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
Biosimilar competition significantly reduces out-of-pocket costs for Medicare patients, enhancing affordability for biologic ...
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
A new study confirms KM118, a proposed biosimilar to pertuzumab, shows pharmacokinetic similarity and safety, paving the way for affordable HER2-positive breast cancer treatments.
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...
In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey has ordered Samsung Bioepis to delay marketing Eticovo until 2029. Samsung Bioepis will ...
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果